BR112017014295A2 - composição farmacêutica. - Google Patents

composição farmacêutica.

Info

Publication number
BR112017014295A2
BR112017014295A2 BR112017014295-3A BR112017014295A BR112017014295A2 BR 112017014295 A2 BR112017014295 A2 BR 112017014295A2 BR 112017014295 A BR112017014295 A BR 112017014295A BR 112017014295 A2 BR112017014295 A2 BR 112017014295A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
combination
benzidamine
ringworm
treatment
Prior art date
Application number
BR112017014295-3A
Other languages
English (en)
Other versions
BR112017014295B1 (pt
Inventor
Milanese Claudio
Capezzone De Joannon Alessandra
Tongiani Serena
Donati Luca
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A
Publication of BR112017014295A2 publication Critical patent/BR112017014295A2/pt
Publication of BR112017014295B1 publication Critical patent/BR112017014295B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere a uma composição farmacêutica compreendendo uma combinação de benzidamina e um ingrediente ativo antimicótico, a dita combinação tendo um efeito sinergístico no tratamento de micose.
BR112017014295-3A 2015-01-13 2016-01-08 Composição farmacêutica. BR112017014295B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15150904.9 2015-01-13
EP15150904 2015-01-13
PCT/EP2016/050272 WO2016113194A1 (en) 2015-01-13 2016-01-08 Pharmaceutical composition for the treatment of mycosis

Publications (2)

Publication Number Publication Date
BR112017014295A2 true BR112017014295A2 (pt) 2018-03-06
BR112017014295B1 BR112017014295B1 (pt) 2023-04-25

Family

ID=52396443

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014295-3A BR112017014295B1 (pt) 2015-01-13 2016-01-08 Composição farmacêutica.

Country Status (29)

Country Link
US (1) US9962372B2 (pt)
EP (1) EP3244889B1 (pt)
JP (1) JP6714597B2 (pt)
KR (1) KR102606081B1 (pt)
CN (1) CN107106690B (pt)
AR (1) AR103381A1 (pt)
AU (1) AU2016208200B2 (pt)
BR (1) BR112017014295B1 (pt)
CA (1) CA2970060C (pt)
CY (1) CY1122979T1 (pt)
DK (1) DK3244889T3 (pt)
EA (1) EA035748B1 (pt)
ES (1) ES2794824T3 (pt)
GE (1) GEP20196962B (pt)
HK (1) HK1246146A1 (pt)
HR (1) HRP20200815T1 (pt)
HU (1) HUE049877T2 (pt)
IL (1) IL252774A0 (pt)
LT (1) LT3244889T (pt)
MD (1) MD3244889T2 (pt)
ME (1) ME03736B (pt)
MX (1) MX2017008879A (pt)
PL (1) PL3244889T3 (pt)
PT (1) PT3244889T (pt)
RS (1) RS60508B1 (pt)
SG (1) SG11201704964RA (pt)
SI (1) SI3244889T1 (pt)
UA (1) UA120864C2 (pt)
WO (1) WO2016113194A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017294402A1 (en) * 2016-07-08 2018-12-20 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Pharmaceutical composition comprising benzydamine
CN112514904B (zh) * 2021-01-26 2021-10-26 青岛农业大学 盐酸苄达明在制备用于防治由植物病原菌引起的植物病害的杀菌剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224598D0 (en) * 1992-11-24 1993-01-13 Smithkline Beecham Plc Novel compositions
IT1274655B (it) * 1995-02-28 1997-07-18 Smithkline Beecham Farma Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico
US6913759B2 (en) * 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
DK2018164T3 (en) 2006-05-12 2017-06-12 Christian Noe Use of combination preparations comprising antimycotics
CN1887352A (zh) * 2006-07-13 2007-01-03 徐艳 治疗眼部真菌和细菌感染的组合物
GB201000196D0 (en) * 2010-01-07 2010-02-24 Galvez Julian M Novel combination

Also Published As

Publication number Publication date
ES2794824T3 (es) 2020-11-19
PT3244889T (pt) 2020-06-04
HK1246146A1 (zh) 2018-09-07
KR102606081B1 (ko) 2023-11-24
HRP20200815T1 (hr) 2020-08-07
JP2018501277A (ja) 2018-01-18
AU2016208200B2 (en) 2020-09-03
ME03736B (me) 2021-01-20
CN107106690A (zh) 2017-08-29
EP3244889A1 (en) 2017-11-22
WO2016113194A1 (en) 2016-07-21
EA201791483A1 (ru) 2017-11-30
CA2970060C (en) 2023-10-03
US20180000783A1 (en) 2018-01-04
HUE049877T2 (hu) 2020-10-28
LT3244889T (lt) 2020-08-10
GEP20196962B (en) 2019-04-10
CN107106690B (zh) 2020-11-10
AU2016208200A1 (en) 2017-06-29
BR112017014295B1 (pt) 2023-04-25
EP3244889B1 (en) 2020-03-04
UA120864C2 (uk) 2020-02-25
IL252774A0 (en) 2017-08-31
AR103381A1 (es) 2017-05-03
RS60508B1 (sr) 2020-08-31
KR20170101941A (ko) 2017-09-06
CY1122979T1 (el) 2021-10-29
SG11201704964RA (en) 2017-07-28
CA2970060A1 (en) 2016-07-21
EA035748B1 (ru) 2020-08-05
DK3244889T3 (da) 2020-06-02
PL3244889T3 (pl) 2020-11-02
MD3244889T2 (ro) 2020-06-30
US9962372B2 (en) 2018-05-08
JP6714597B2 (ja) 2020-06-24
SI3244889T1 (sl) 2020-08-31
MX2017008879A (es) 2018-03-28

Similar Documents

Publication Publication Date Title
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
BR112018004532A2 (pt) uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
BR112018072467A2 (pt) composições farmacêuticas com permeação aumentada
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
BR112018072539A2 (pt) composições de epinefrina de administração aumentada
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112016014880A2 (pt) Composição farmacêutica incluindo palonosetron
BR112017021190A2 (pt) composição farmacêutica e o uso da mesma
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
BR112018004291A2 (pt) composição farmacêutica incluindo dutasterida e formulação de cápsula compreendendo a mesma
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
CY1122979T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της μυκητιασης
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
EA201890477A1 (ru) Инкапсулированная композиция финголимода
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
BR112018007374A2 (pt) composição farmacêutica
AR104200A1 (es) Carboximetilcisteina para tratamiento tópico de estrías

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/01/2016, OBSERVADAS AS CONDICOES LEGAIS